drugset / Trial / NCT07109414
Trial of NP-G2-044 (Prilukae) Combined With PLD for Treatment of Platinum-Resistant Ovarian Cancer (ULTIMUS-1)
Phase 2/3
Active not recruiting
380 enrolled
Novita Pharmaceuticals, Inc.
Gynecologic Oncology Group · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of the study is to identify the optimal dose level of NP-G2-044 in combination with standard of care (SOC) pegylated liposomal doxorubicin (PLD), and to compare the efficacy and safety of NP-G2-044+PLD vs. PLD alone in participants with platinum-resistant ovarian cancer (PROC).
Timeline
- Start
- 2025-12-29
- Primary completion
- 2028-10-25
- Completion
- 2029-10-24
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | NP-G2-044 | Small molecule | — | Oral |
| Subject | PLD | Unknown | — | Intravenous |